NCT06649253 Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
| NCT ID | NCT06649253 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rennes University Hospital |
| Condition | Leukemia, Lymphoblastic, Acute, Pediatric |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-03-22 |
| Primary Completion | 2035-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-03-22 with a primary completion date of 2035-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Eligibility Criteria
Inclusion Criteria: * Under 18 years * With established diagnosis of B-ALL * Initial diagnosis made in the investigating centre * Having received oral and written information about the protocol, or oral only if the patient is unable to read. * Having signed a consent form if the patient is capable of giving informed written consent. * Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent. * Beneficiary of a social security scheme Exclusion Criteria: * Isolated extramedullary involvement at inclusion * Patient of childbearing age without effective contraception. * Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Contact & Investigator
Elie COUSIN
STUDY CHAIR
University of Rennes
Frequently Asked Questions
Who can join the NCT06649253 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 17 Years, studying Leukemia, Lymphoblastic, Acute, Pediatric. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06649253 currently recruiting?
Yes, NCT06649253 is actively recruiting participants. Contact the research team at elie.cousin@univ-rennes.fr for enrollment information.
Where is the NCT06649253 trial being conducted?
This trial is being conducted at Angers, France, Brest, France, Rennes, France.
Who is sponsoring the NCT06649253 clinical trial?
NCT06649253 is sponsored by Rennes University Hospital. The principal investigator is Elie COUSIN at University of Rennes. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.